Rabies immune globulin
As of the edition of 20 October 2026, Rabies immune globulin is a drug: marketed, first approved in 1974 (US); US protection ended in 1986.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Unknown
- Brand name
- Bayrab
- First approved
- 12 June 1974 (US)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- Grifols Therapeutics; 3 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Infections
US protection
US protection ended in 1986.
US protection ended in 1986, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Grifols Therapeutics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Grifols Therapeutics | Applicant | 1974 to now |
| Sanofi | Later holder and Lead sponsor of trials | 2001 to now |
| Kamada | Later holder and Lead sponsor of trials | 2016 to now |